A Phase I, Randomized, Single-Blind, Single-Dose, Three-Arm, Parallel-Group Study Assessing the Pharmacokinetic Similarity of Biosimilar ABP215 to Bevacizumab Reference Product Sourced from the US and the EU in Healthy Adult Male Subjects

Trial Profile

A Phase I, Randomized, Single-Blind, Single-Dose, Three-Arm, Parallel-Group Study Assessing the Pharmacokinetic Similarity of Biosimilar ABP215 to Bevacizumab Reference Product Sourced from the US and the EU in Healthy Adult Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Breast cancer; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma
  • Focus First in man; Pharmacokinetics
  • Most Recent Events

    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 18 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top